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Summary 
Suramin is a polyanionic compound which has been used in the treatment of trypanosomiasis and 
acquired i~unodefi~iency syndrome (AIDS), while preli~na~ success has been reported in the 
treatment of cancer. However, suramin also causes adrenal insufficiency. We have previously reported that 
suramin selectively inhibited corticotropin (ACTH)-stimulated corticosterone release by dispersed adrenal 
cells in a dose-dependent manner via a direct interaction with the ACTH molecule. The present study was 
undertaken in order to investigate the effect of suramin on hormone release by dispersed rat anterior 
pituitary cells. Suramin at a concentration of 100 PM inhibited both basal and secretagogue-stimulated 
ACTH release by cells cultured in vernal essential medium (MEM) only, while it had no effect on ACTH 
release by cells cultured in MEM + 10% fetal calf serum (FCS) or MEM + 0.1% bovine serum albumin 
(BSA). In addition, suramin also caused a parallel decrease of prolactin (PRL) and growth hormone (GH) 
release by cells cultured in MEM only, suggesting a toxic, rather than a selective effect of suramin on 
anterior pituitary cells cultured in MEM only. In addition, suramin potentiated the effect of thyrotropin- 
releasing hormone (TRH) on PRL release by cells cultured in MEM + 10% FCS and suppressed the 
in~bito~ effect of dopamine (DA) on PRL release by cells cultured in MEM + 10% FCS and in 
MEM + 0.1% BSA. Comparable suppressive effects of suramin on growth hormone-releasing hormone 
(GHRH)-stimulated and somatostatin (SRIH)-inhibited GH release were found in cells cultured in 
MEM + 0.1% BSA but not in cells cultured in MEM + 10% FCS. Finally, suramin blocked the bovine 
follicular fluid (bFF)-mediated inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH) release by cells cultured in MEM + 10% FCS, probably via a direct interaction with inhibin in the 
bFF. From these results we conclude that: (1) the effect of suramin on the h~othalamo-pituitary-adrenal 
axis appears to be mainly restricted to the adrenals, because its inhibitory effects on ACTH release by 
dispersed anterior pituitary cells appears to be nonspecific, being prevented by adding 0.1% BSA or 10% 
FCS. (2) The effect of suramin on PRL and GH release in response to their secretagogues is variable and 
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dependent on the protein environment of the cells. (3) The effect of suramin on bFF-mediated inhibition 
of FSH and LH release by pituitary cells seems to be rather specific through an interaction with inhibin 
and abolishment of its inhibitory effects on FSH and LH release. 
Introduction 
Suramin sodium, the sodium salt of sulfonated 
naphthyl polyurea which contains six reactive 
sulfonic acid carbonyl groups (Fig. l), was initially 
introduced for the treatment of African trypano- 
sorniasis (sleeping sickness), onchocerciasis and 
pemphigus (Wanson, 1950; Aptel, 1970). Being a 
reverse transcriptase inhibitor (De Clercq, 1979) 
it has also been evaluated as a potential treatment 
for viral infections in immunodeficient humans 
and for the acquired immunodeficiency syndrome 
(AIDS) (Mitsuya et al., 1984; Broder et al., 1985; 
De Clercq, 1987). Thereafter it was found that 
suramin inhibits the binding of platelet-derived 
growth factor to its receptor (Hosang, 1985; 
Johnsson et al., 1986). More recently suramin was 
described as a relatively selective competitive 
antagonist for several growth factor receptors, 
suggesting that suramin might be effective in the 
treatment of cancer (Betcholtz et al., 1986). How- 
ever, several investigators have reported on the 
occurrence of adrenal insufficiency during therapy 
with this drug (Azerad and Grupper, 1953; Che- 
son et al., 1986; Stein et al., 1986). We have 
previously shown that suramin prevents corti- 
cotropin (ACTH)-stimulated corticosterone re- 
lease by dispersed rat adrenocortical cells in vitro 
(Marzouk et al., 1990). However, it did not pre- 
vent cholera toxin-, forskolin- and dibutyryl cyclic 
AMP (dbcAMP)-stimulated corticosterone release, 
indicating a selective loss of ACTH stimulatory 
effects on adrenocortical cells. 
S03Na 
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Fig. 1 Structural formula of suramin. 
In the present study we evaluated the effect of 
suramin on basal and secretagogue-altered hor- 
mone release by dispersed rat anterior pituitary 
cells. 
Materials and methods 
Experimental animals 
Female RP rats or male R-Amsterdam rats, 
weighing 180-200 g, were kept in an artificially 
illuminated room (08.30-20.30 h) with food and 
water ad libitum. The animals, in any stage of the 
estrous cycle, were killed by decapitation between 
08.00 and 09.00 h. The pituitary glands were re- 
moved within 5 min after killing, the neurointer- 
mediate lobe was discarded, and the anterior lobes 
were collected in calcium- and magnesium-free 
Hanks’ balanced salt solution (HBSS; Gibco, Pais- 
ley, U.K.) supplemented with 10 g/l human serum 
albumin, penicillin (lo5 U/l), streptomycin (100 
mg/l), fungizone (0.5 mg/l) and sodium bi- 
carbonate (0.4 g/l). 
Pituitary cell culture 
The anterior pituitary lobes were dissociated 
with dispase, a neutral protease from Bacillus 
polymyxa (grade II, final concentration 2.4 X lo3 
U/l; Boehringer Mannheim, Mannheim, F.R.G.) 
as described in detail previously (Oosterom et al., 
1983a). Viability of the cells, as determined by 
trypan blue exclusion, was greater than 90%. The 
dispersed cells were cultured in a culture medium 
consisting of minimal essential medium with 
Earle’s salts (MEM; Gibco) supplemented with 
non-essential amino acids, sodium pyruvate (1 
mmol/l), 10% fetal calf serum (FCS), penicillin 
(lo5 U/l), streptomycin (100 mg/l), fungizone 
(0.5 mg/l), L-glutamine (2 mmol/l) and sodium 
bicarbonate (2.2 g/l final concentration). The 
medium was adjusted to pH 7.5 with 1 mol/l 
NaOH. lo5 cells per well per 1 ml culture medium 
were plated in 48-well plates (Coster, Cambridge, 
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MA, U.S.A.). The studies on ACTH release were 
carried out after 2 days of culture, since this was 
previously shown to be the most suitable time of 
measuring optimal ACTH release by cultured 
pituitary cells (Lamberts et al., 1986). The studies 
on prolactin (PRL), growth hormone (GH), 
luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) release were carried out between 
days 4 and 7 (Oosterom et al., 1983a; Grootenhuis 
et al., 1989). The media were refreshed prior to 
incubation times which were 3 h in the studies on 
ACTH release, 4 h in the studies on PRL and GH 
release and 6 or 72 h in the studies on LH and 
FSH release. No pre-incubations with the investi- 
gational compounds were performed. Incubation 
studies were carried out in MEM only, MEM + 
10% FCS or MEM + 0.1% bovine serum albumin 
(BSA). All studies were done in quadruplicate. At 
the end of the incubation the media were collected 
and centrifuged during 5 min at 600 X g. The 
supernatants were stored at - 20 o C until analysis. 
The media in which ACTH was determined were 
adjusted to pH 3.5 using 1.0 N HCl. 
Investigational compounds 
Ovine corticotropin-releasing factor (oCRF) 
was obtained from UCB Bioproducts (Brussels, 
Belgium), vasopressin (VP) from Sandoz (Basle, 
Switserland), suramin from Bayer (Leverkusen, 
F.R.G.), growth hormone-releasing hormone (GH- 
RH) from Universal Biologicals (Cambridge, 
U.K.), thyrotropin-releasing hormone (TRH) and 
luteinizing hormone-releasing hormone (LHRH) 
from Hoechst (Amsterdam, The Netherlands), for- 
skolin from Calbiochem (La Jolla, CA, U.S.A.) 
and potassium chloride (KCl) from Merck 
(Darmstadt, F.R.G.). Dopamine (DA), soma- 
tostatin (SRIH), dibutyryl cyclic adenosine mono- 
phosphate (dbcAMP) and cholera toxin were 
purchased from Sigma (St. Louis, MA, U.S.A.). 
Norepinephrine (NE) was supplied by the Univer- 
sity Hospital Dijkzigt pharmacy (Rotterdam, The 
Netherlands). Charcoal-treated bovine ovarian 
follicular fluid (bFF) was prepared as described 
previously (Grootenhuis et al., 1989). 
Hormone assays 
The ACTH concentration in the media was 
determined by radioimmunosorbent assay (RIA) 
using a commercially available kit from Medgenix 
(Fleurus, Belgium). Intra-assay and inter-assay 
variation amounted to 6.2% and 5.8% respectively. 
Rat GH and rat PRL concentrations were de- 
termined by RIA as described previously (Ooster- 
om et al., 1983a, b). Intra- and inter-assay varia- 
tions were 8% and 11% for GH and 5% and 8% for 
PRL respectively. LH and FSH concentrations 
were determined by RIA as described previously 
(Grootenhuis et al., 1989) using the antiserum 
described by Welschen et al. (1975). Intra- and 
inter-assay variations varied between 10% and 15%. 
The addition of a sample volume containing 1 
mM of suramin had no effect on the initial bind- 
ing in the RIAs for PRL and LH but it inhibited 
the initial binding of the RIAs for ACTH, FSH 
and GH. We overcame interference of suramin in 
the ACTH and FSH RIAs by diluting the media 
at least 10 and 5 times respectively. 100 PM and 
200 PM suramin had no effect on the initial 
binding of the RIAs for ACTH and FSH while it 
still reduced the initial binding in the GH RIA. 
The suramin present in the media, however, did 
not affect GH RIA data because the samples were 
routinely diluted 25 times prior to GH measure- 
ment. Each experiment described was repeated at 
least twice with similar results. 
Results are expressed as means + SEM and 
statistical evaluation was done using one-way 
analysis of variance (ANOVA). Log-transforma- 
tion of data was used to stabilize variance. For the 
comparison of differences between means the 
Newman-Keuls method was applied (Snedecor and 
Cochran, 1980); p < 0.05 was considered signifi- 
cant. 
Results 
Effects of suramin on ACTH release 
First the effect of increasing concentrations of 
suramin was evaluated on basal and corticotropin- 
releasing hormone (CRH) (1 nM)-stimulated 
ACTH release by cultured normal rat anterior 
pituitary cells (Fig. 2). In cells cultured in MEM 
+ 10% FCS or in MEM + 0.1% BSA neither basal 
nor CRH-stimulated ACTH release was signifi- 
cantly affected by suramin, even at a concentra- 
tion of 100 PM. If the cells were cultured in MEM 
only, however, suramin at concentrations between 
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Fig. 2. The effect of increasing concentrations of suramin on 
basal (- - - - - -) and CRH (1 nM)-stimulated ( -) ACTH 
release by cultured normal rat pituitary cells. Data are mean f 
SEM. Culture media were (A) MEM + 10% FCS, (0) MEM + 
0.1% BSA and (m) MEM only. * p < 0.01 vs. basal release 
(without suramin) and vs. CRH only. 
0.1 PM and 10 PM did not significantly affect 
ACTH release, while 100 PM suramin signifi- 
cantly inhibited basal and CRH-stimulated ACTH 
release ( p < 0.01 versus respective controls without 
suramin in both instances). 
The mechanism of suramin (100 PM)-mediated 
inhibition of ACTH release by cells cultured in 
MEM only was further investigated in the pres- 
ence of several compounds that stimulate ACTH 
release by different mechanisms. This is shown in 
Fig. 3. 100 PM suramin significantly inhibited 
CRH (1 nM)-, cholera toxin (10 mg/l)-, forskolin 
(5 PM)-, potassium chloride (56 mM)-, dbcAMP 
(5 mM)-, vasopressin (VP) (100 U/l)- and 
norepinephrine (NE) (1 PM)-stimulated ACTH 
release to a similar extent ( p < 0.01 in all in- 
stances), while 1 and 10 PM suramin had no 
significant effect. 
Effects of suramin on GH and PRL release 
The effect of suramin (100 PM) on TRH- 
stimulated PRL release is shown in Fig. 4. The 
addition of 100 PM suramin had a synergistic 
effect on TRH-stimulated PRL release by cells 
cultured in MEM + 10% FCS (Fig. 4, Table 1; 
p < 0.01 vs. TRH alone at TRH concentrations 
higher than 0.1 nM), while this effect was not 
present in cells cultured in MEM + 0.1% BSA 
(Table 1). Suramin (100 PM) significantly lowered 
the inhibitory effect of DA (500 nM) on PRL 
release by cells cultured in MEM + 10% FCS and 
in MEM + 0.1% BSA (Table 1). 100 PM suramin 
TABLE 1 
THE EFFECT OF 100 PM SURAMIN ON TRH (100 nM)-STIMULATED AND DA (500 nM)-INHIBITED PRL RELEASE BY 
RAT ANTERIOR PITUITARY CELLS CULTURED IN MEM + 10% FCS OR IN MEM +O.l% BSA 
Data are mean + SEM; values in brackets are percentage stimulation (+ ) or inhibition ( -). 
Culture medium Drug (nM) Suramin (PM) 
MEM + 10% FCS _ _ 
MEM + 10% FCS _ 100 
MEM + 10% FCS TRH (100) _ 
MEM + 10% FCS TRH (100) 100 
MEM + 10% FCS DA (500) _ 
MEM + 10% FCS DA (500) 100 
MEM+O.l% BSA _ 
MEM+O.l% BSA _ 100 
MEM + 0.1% BSA TRH (100) _ 
MEM + 0.1% BSA TRH (100) 100 
MEM +O.l% BSA DA (500) _ 
MEM+O.l% BSA DA (500) 100 
’ p < 0.01 vs. control (no drug + no suramin); b p < 0.01 vs. TRH; ‘p < 0.01 vs. DA. 
rPRL (ng/well/4 h) 
670* 2 
82Ok21 (+22%) a 
1472*38 (+120%) * 
1900 * 60 (+ 184%) a.b 
280+15 (-58%) = 
345+39 (-44%) B,c 
760+ 16 
810+44 
1863+59(+145%)” 
2027 5 97 ( * 167%) a 
203+12 (-73%) * 
353*27 (-54%) =.‘ 
99 
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Fig. 3. The effect of suramin on CRH (1 nM)-, cholera toxin (10 mg/l)-, forskolin (S PM)-, potassium chloride (56 mM)-. dbcAMP (5 
mM)-, vasopressin (100 U/l)- and norepinephrine (1 pM)-stimulated ACTH release by normal rat anterior pituitary cells cultured in 
MEM only. Data are mean + SEM; the dotted line represents the basal ACTH release. * p < 0.01 vs. all the mentioned secretagogues. 
had no significant effect on GHRH-stimulated 
and SRIH-inhibited GH release by cells cultured 
in MEM + 10% FCS, while it inhibited the GHRH 
stimulatory effect on GH release by cells cultured 
in MEM + 0.1% BSA (Table 2). In addition 
suramin significantly decreased the SRIH inhibi- 
TABLE 2 
THE EFFECT OF 100 PM SURAMIN ON GHRH (IO-nM)-STIMULATED AND SRIH (1 nM)-INHIBITED GH RELEASE BY 
RAT ANTERIOR PITUITARY CELLS CULTURED IN MEM + 10% FCS OR IN MEM + 0.1% BSA 
Data are mean + SEM; values in brackets are percentage of stimulation (+) or inhibition (- ). 
Culture medium Drug (nM) Suramin (CM) rGH (ng/well/4 h) 
MEM + 10% FCS _ 78f 4 
MEM + 10% FCS 100 84k 4 
MEM + 10% FCS GHRH (10) 292 f 17 (+ 273%) a 
MEM + 10% FCS GHRH (10) 100 2715 6(+246%)a 
MEM + 10% FCS SRIH (1) 48k 3 (-39%)a 
MEM + 10% FCS SRIH (1) 100 36i 4 (-54%)= 
MEM+O.l% BSA _ 137* 4 
MEM+O.l% BSA _ 100 13Ok 6 
MEM+O.l% BSA GHRH (10) 54Of21(+293%) a 
MEM+O.l% BSA GHRH (10) 100 351 f 16 (+ 156%) a.b 
MEM+O.l% BSA SRIH (1) 61+ 4 (-56%)= 
MEM + 0.1% BSA SRIH (1) 100 96f 4 (-30%)a,C 
a p i 0.01 vs. control (no drug+no suramin); bp i 0.01 vs. GHRH; and 'p < 0.01 vs. SRIH. 
100 
tory effect on GH release by cells cultured in 
MEM + 0.1% BSA. Finally, in cells cultured in 
MEM only 100 PM suramin virtually completely 
suppressed both basal GH and basal PRL release 
(data not shown). 
Effects of suramin on gonadotrophin release 
100 JLM suramin significantly stimulated the 
basal FSH release without having a significant 
effect on basal LH release (Fig. 5; p -C 0.01 vs. 
control). On the other hand, 100 PM of suramin 
caused a decrease of bFF (1.12 nl/ml)-mediated 
inhibition on FSH and LH release by cells cul- 
tured in MEM + 10% FCS (Fig. 5). FSH values 
increased to 173 k 12% of those after the addition 
of bFF alone, whereas LH concentrations in- 
creased to 130 + 7% of the bFF control value. 
This difference is statistically significant ( p <: 
0.05). In order to study the effect of suramin on 
LHRH-stimulated FSH and LH release we per- 
formed 6-h incubation experiments. 100 PM of 
suramin had no effect on basal or LHRH-stimu- 
lated FSH and LH release by cells cultured in 
MEM + 10% FCS (data not shown). 
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Fig. 4. The effect of 100 PM suramin on TRH-stimulated PRL 
release by rat anterior pituitary cells cultured in MEM + 10% 
FCS. Data are meanf SEM. (e) TRH alone, (A) TRH+ 
suramin (100 PM). * p < 0.01 vs. control; * * p < 0.01 vs. TRH 
alone. 
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Fig. 5. The effect of suramin on basal and bFF (1.12 nl/ml 
culture medium)-inhibited LH and FSH release by rat anterior 
pituitary cells cultured in MEM + 10% FCS. Data are mean + 
SEM. * p i 0.01 vs. basal LH and FSH release (without 
suramin); l p < 0.01 vs. bFF alone. 
Discussion 
Suramin, a polyanionic compound, has been 
demonstrated to inhibit a wide variety of biologic 
actions in different systems (Hawing, 1978; 
Mitsuya et al., 1985) via its binding with proteins 
of all kinds, including albumin, globulins, fibrin- 
ogen, histones and a wide variety of enzymes (De 
Clercq, 1987). Inhibition of glycerol-3-phosphate 
oxidase and NAD+-dependent glycerol-3-phos- 
phate dehydrogenase, two key enzymes in glycoly- 
sis, explains the antiparasitic action of suramin 
(Fairlamb and Bowman, 1980). 
Pituitary cells probably undergo functional 
changes when their microenvironments are varied 
(Martin, 1985). We have investigated the effect of 
suramin on hormone release by dispersed rat ante- 
rior pituitary cells cultured in medium without 
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serum, and in medium containing 10% FCS or 
0.1% BSA. We have used suramin concentrations 
up to 100 PM because this concentration is near 
to the therapeutic concentration used in the treat- 
ment of AIDS (Stein et al., 1986). Suramin at a 
concentration of 100 PM inhibited both basal and 
secretagogue-stimulated ACTH release by disper- 
sed anterior pituitary cells cultured in MEM only, 
while it had no effect on ACTH release by cells 
cultured in MEM + 10% FCS or MEM + 0.1% 
BSA. Basal ACTH release was also significantly 
inhibited by 100 PM suramin in cells cultured in 
MEM only. Suramin (10 PM) has been previously 
reported to inhibit albumin (100 PM)-mediated 
stimulation of LH-stimulated steroid production 
by Leydig cells (Bos, 1988). This suggests that in 
our present study, albumin may interact with 
suramin and prevent its inhibitory effects on 
hormone release. This might also mean that the 
inhibitory effect of suramin (100 PM) on hormone 
release by pituitary cells cultured in media without 
protein is non-specific. A toxic effect seems to be 
the most likely explanation as suramin also in- 
hibited GH and PRL secretion by cells cultured in 
MEM only. However, if the protein content of 
culture medium was changed, the effect of sura- 
rnin (100 PM) on basal and secretagogue-stimu- 
lated GH and PRL release greatly varied. Suramin 
potentiated TRH-stimulated PRL release by pitui- 
tary cells cultured in MEM + 10% FCS, while it 
partially antagonized the inhibitory effect of DA 
on PRL release by pituitary cells cultured in 
MEM + 10% FCS as well as in MEM + 0.1% BSA. 
With respect to GH release suramin inhibited 
GHRH-stimulated GH release by cells cultured in 
MEM + 0.1% BSA, while it partially antagonized 
the SRIH-inhibited GH release by cells cultured 
in MEM + 0.1% BSA. 
Interestingly, 100 I_~M of suramin stimulated 
basal FSH release and antagonized the inhibitory 
effect of bFF on FSH and LH release by pituitary 
cells cultured in MEM + 10% FCS in 72-h incuba- 
tion experiments, whereas in 6-h incubation stud- 
ies the addition of 100 PM suramin had no effect 
on basal and LHRH-stimulated FSH and LH 
release. These effects are probably due to the 
interference of suramin with inhibin, a glycopro- 
tein which inhibits pituitary gonadotrophin pro- 
duction and/or secretion, preferentially that of 
FSH (Burger, 1988). Inhibin is present in the bFF 
(De Jong and Sharpe, 1976) and may be produced 
in the pituitary cells (Roberts et al., 1989). Jansen 
et al. (1981) have previously reported on the bind- 
ing of inhibin with Procion red HE3B, a poly- 
anionic dye with a structure similar to that of 
suramin. Interestingly, preliminary observations 
showed that Procion red HE3B also inhibited 
ACTH-stimulated corticosterone release by adre- 
nal cells to a similar extent as that observed with 
suramin (unpublished observations). These studies 
suggest that suramin probably binds to the inhibin 
molecules in the bFF and thus antagonizes its 
inhibitory effects on FSH and LH release. This 
hypothesis is substantiated, firstly, because sura- 
min caused suppression of bFF-mediated inhibi- 
tion of FSH and LH release and secondly, because 
the effect of surarnin is greater on the bFF-media- 
ted inhibition of FSH release than on that of LH 
release. 
It is difficult, however, to envisage why suramin 
(100 PM) has no effect on CRH-stimulated ACTH 
release by cells cultured in MEM + 10% FCS and 
MEM + 0.1% BSA, no effect on LHRH-stimu- 
lated FSH and LH release, while it has variable 
effects on GHRH-stimulated and SRIH-inhibited 
GH release and TRH-stimulated and DA-in- 
hibited PRL release by these cells. As the proper- 
ties of amino acid side chains are important for 
the conformation and function of proteins, for the 
most part, amino acid with charged, polar or 
hydrophilic side chains are exposed on the surface 
of proteins, whereas the non-polar, hydrophobic 
ones are tucked away inside proteins out of con- 
tact with water (Rawn, 1989). The chemical struc- 
ture of GHRH and SRIH has more basic amino 
acids which renders them with a strong positive 
charge while the structures of CRH and LHRH 
have nearly equal basic and acidic amino acids. 
The suramin molecules has six negative charges on 
its surface suggesting a more powerful interaction 
between suramin and GHRH and SRIH than with 
the CRH and LHRH molecules. The increase in 
SRIH-inhibited GH release by 100 PM suramin 
by cells cultured in MEM + 10% FCS might be 
explained by interference of suramin with a fac- 
tor(s) present in the FCS which affects SRIH-in- 
hibited GH release. TRH has no charge, suggest- 
ing that the synergistic effect of suramin could be 
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explained by interaction of suramin with other 
factor(s) in the FCS which inhibit PRL release. 
For example, suramin might interact with the PRL 
molecule itself, intervening its direct negative 
feedback effect at the level of the lactotroph 
(Frawley and Clark, 1986). 
In summary we suggest that at 100 PM suramin 
binds to protein molecules in the media with dif- 
ferent affinities leading to no effect on CRH- 
stimulated ACTH release, no effect on LHRH- 
stimulated FSH and LH release and variable ef- 
fects on GH and PRL release. The effect of 
suramin on bFF-mediated inhibition of FSH and 
LH release, however, seems different. Suramin 
molecules seem to bind the inhibin preferably 
rather than to exert non-specific effects on the 
cultured gonadotrophs. 
The fact that suramin combines with a great 
variety of proteins results, on the one hand, in a 
lack of specificity, but on the other hand, it also 
prevents suramin from being eliminated prema- 
turely, permitting the compound to reach suffi- 
ciently high blood levels at a dosage regimen of 
one injection of 1.0 g suramin per week (Collins et 
al., 1986). Suramin binds for at least 99.7% to 
plasma proteins, mainly the albumin. As the affin- 
ity of suramin binding with albumin is high and 
the albumin concentration of the human plasma is 
3.5-4.5 g/dl, albumin offers probably consider- 
able protection against the inhibitory effects of 
suramin on pituitary hormone release in vivo. 
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